NO333676B1 - Nytt konstruert superantigen for human terapi - Google Patents

Nytt konstruert superantigen for human terapi Download PDF

Info

Publication number
NO333676B1
NO333676B1 NO20035773A NO20035773A NO333676B1 NO 333676 B1 NO333676 B1 NO 333676B1 NO 20035773 A NO20035773 A NO 20035773A NO 20035773 A NO20035773 A NO 20035773A NO 333676 B1 NO333676 B1 NO 333676B1
Authority
NO
Norway
Prior art keywords
sea
amino acid
superantigen
region
antibody
Prior art date
Application number
NO20035773A
Other languages
English (en)
Norwegian (no)
Other versions
NO20035773L (no
Inventor
Goran Forsberg
Per Antonsson
Eva Erlandsson
Bjorn Walse
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of NO20035773L publication Critical patent/NO20035773L/no
Publication of NO333676B1 publication Critical patent/NO333676B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/06—Message adaptation to terminal or network requirements
    • H04L51/063—Content adaptation, e.g. replacement of unsuitable content
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/58—Message adaptation for wireless communication

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20035773A 2001-06-28 2003-12-22 Nytt konstruert superantigen for human terapi NO333676B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102327A SE0102327D0 (sv) 2001-06-28 2001-06-28 A novel engineered superantigen for human therapy
PCT/SE2002/001188 WO2003002143A1 (en) 2001-06-28 2002-06-19 A novel engineered superantigen for human therapy

Publications (2)

Publication Number Publication Date
NO20035773L NO20035773L (no) 2004-02-27
NO333676B1 true NO333676B1 (no) 2013-08-05

Family

ID=20284677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035773A NO333676B1 (no) 2001-06-28 2003-12-22 Nytt konstruert superantigen for human terapi

Country Status (28)

Country Link
US (3) US7125554B2 (xx)
EP (1) EP1406657B1 (xx)
JP (1) JP4523773B2 (xx)
KR (1) KR100961054B1 (xx)
CN (1) CN1522156B (xx)
BG (1) BG66321B1 (xx)
BR (1) BRPI0210568B8 (xx)
CA (1) CA2451847C (xx)
CZ (1) CZ307180B6 (xx)
DK (1) DK1406657T3 (xx)
EE (1) EE05475B1 (xx)
ES (1) ES2564041T3 (xx)
HK (1) HK1067980A1 (xx)
HR (1) HRP20031054B1 (xx)
HU (1) HUP0400313A3 (xx)
IL (2) IL159562A0 (xx)
IS (1) IS2986B (xx)
MX (1) MXPA03011761A (xx)
NO (1) NO333676B1 (xx)
NZ (1) NZ529827A (xx)
PL (1) PL216516B1 (xx)
RS (1) RS52581B (xx)
RU (1) RU2307837C2 (xx)
SE (1) SE0102327D0 (xx)
SK (1) SK16112003A3 (xx)
UA (1) UA85993C2 (xx)
WO (1) WO2003002143A1 (xx)
ZA (1) ZA200309150B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
JP2001510687A (ja) * 1997-07-21 2001-08-07 フアーマシア・アンド・アツプジヨン・アー・ベー 標的細胞の指向細胞溶解、細胞溶解を引き起こす薬剤および組成物、ならびにそのような薬剤を製造するために使用できる化合物
US7491402B2 (en) * 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
US20040241703A1 (en) * 2002-08-19 2004-12-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
EP1609860B1 (en) * 2003-03-28 2010-03-17 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Seb modification and preventive/remedy for diseases with immune abnormality containing the same
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
JP2008520227A (ja) * 2004-11-18 2008-06-19 メディジーン リミテッド 可溶性二官能性タンパク質
GB0427585D0 (en) * 2004-12-16 2005-01-19 Avidex Ltd Assay
JP2010516786A (ja) * 2007-01-26 2010-05-20 ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション，インコーポレーテッド ワクチンとしての使用のためのエキソソーム成分の改変
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN102516392B (zh) * 2011-11-25 2014-05-28 孙嘉琳 一种癌靶向超抗原融合蛋白及制备方法及用途
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
CN103965302B (zh) * 2013-01-29 2019-05-28 军事科学院军事医学研究院微生物流行病研究所 一种重组超抗原seb突变体，其制备方法及应用
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
CN109195988B (zh) 2016-01-10 2023-12-01 尼奥克斯医疗有限公司 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
CA3069747A1 (en) 2017-07-27 2019-01-31 Mohammad Javad Aman Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
KR20220009428A (ko) 2019-05-15 2022-01-24 네오티엑스 테라퓨틱스 엘티디. 암 치료
EP4114449A2 (en) 2020-03-05 2023-01-11 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
AU2021350860A1 (en) * 2020-09-28 2023-05-04 Janssen Pharmaceuticals, Inc. Variant staphylococcusaureus luka and lukb polypeptides and vaccine compositions
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US6042837A (en) 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
DE69133068T2 (de) * 1990-01-17 2003-03-13 David S Terman Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
DE69112207T2 (de) 1990-04-05 1996-03-28 Roberto Crea "walk-through"-mutagenese.
US5858363A (en) 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
WO1993024136A1 (en) 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
AU1570292A (en) 1991-02-07 1992-09-07 Board Of Trustees Of The University Of Illinois, The Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
CA2126438C (en) 1991-12-24 2003-12-02 Jac A. Nickoloff Site-directed mutagenesis of dna
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5545716A (en) 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5519114A (en) 1993-10-29 1996-05-21 University Of Florida Research Foundation, Inc. Retroviral superantigens, superantigen peptides, and methods of use
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
US5935568A (en) 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US6632441B2 (en) 1995-06-07 2003-10-14 Regents Of The University Of Minnesota Mutants of streptococcal toxin a and methods of use
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
JP4110485B2 (ja) 1996-03-27 2008-07-02 ウステル・テヒノロジーズ・アクチエンゲゼルシヤフト 糸の品質を監視する方法及び装置
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
WO1997036614A1 (en) 1996-03-29 1997-10-09 Terman David S Polymerized staphylococcal protein a for treatment of diseases
ES2260804T3 (es) 1996-12-06 2006-11-01 Regents Of The University Of Minnesota Mutante de la toxina estreptococica c y metodos de uso.
US6774218B2 (en) 1996-12-06 2004-08-10 Regents Of The University Of Minnesota Mutants of streptococcal toxin C and methods of use
US6913755B2 (en) 1996-12-06 2005-07-05 Regents Of The University Of Minnesota Mutants of Streptococcal toxin A and methods of use
WO1998026747A2 (en) 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
IL119938A (en) 1996-12-30 2005-08-31 Yissum Res Dev Co Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
JP2001510687A (ja) 1997-07-21 2001-08-07 フアーマシア・アンド・アツプジヨン・アー・ベー 標的細胞の指向細胞溶解、細胞溶解を引き起こす薬剤および組成物、ならびにそのような薬剤を製造するために使用できる化合物
WO1999036433A2 (en) 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
DE69940157D1 (en) 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
US20010046501A1 (en) 2000-03-14 2001-11-29 Johnson Howard M. Superantigen enhancement of specific immune responses
JP4283430B2 (ja) 2000-09-26 2009-06-24 株式会社カネカ エンテロトキシンの吸着材、吸着除去方法および吸着器
EP1349568B1 (en) 2000-12-04 2009-09-16 Auckland Uniservices Limited Immunomodulatory constructs and their uses
CN1369550A (zh) 2001-02-16 2002-09-18 沈阳协合集团有限公司 一种金黄色葡萄球菌的培养物及其制备方法
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
BR0313638A (pt) * 2002-08-21 2005-06-21 Merck Patent Ges Mit Berschron Epìtopos de células t na enterotoxina b em estafilococos
US20090162315A1 (en) * 2004-06-29 2009-06-25 Terman David S Enterotoxin gene cluster (egc) superantigens to treat malignant disease
US20060005711A1 (en) 2004-07-07 2006-01-12 Andrew Olefson Replaceable filter for a vehicle air conditioning system adapted to scent air
SE0402025D0 (sv) 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
US20070280905A1 (en) * 2006-06-01 2007-12-06 Shulin Li Prognosis and Systemic Therapy for Treating Malignancy

Also Published As

Publication number Publication date
CZ20033559A3 (en) 2004-06-16
HUP0400313A2 (hu) 2004-09-28
PL368048A1 (en) 2005-03-21
EE05475B1 (et) 2011-10-17
KR100961054B1 (ko) 2010-06-01
KR20040015264A (ko) 2004-02-18
EP1406657B1 (en) 2015-12-30
BRPI0210568B1 (pt) 2020-10-13
IS2986B (is) 2017-09-15
RS52581B (en) 2013-04-30
CA2451847A1 (en) 2003-01-09
EP1406657A1 (en) 2004-04-14
HUP0400313A3 (en) 2006-02-28
DK1406657T3 (en) 2016-03-07
NO20035773L (no) 2004-02-27
US20100111978A1 (en) 2010-05-06
WO2003002143A1 (en) 2003-01-09
HRP20031054A2 (en) 2004-04-30
CN1522156B (zh) 2012-10-10
RU2004102199A (ru) 2005-05-20
UA85993C2 (ru) 2009-03-25
CN1522156A (zh) 2004-08-18
BR0210568A (pt) 2004-08-03
SK16112003A3 (en) 2004-11-03
PL216516B1 (pl) 2014-04-30
MXPA03011761A (es) 2004-04-02
ZA200309150B (en) 2005-01-26
YU101503A (xx) 2006-05-25
EE200400037A (et) 2004-04-15
BG108499A (en) 2005-03-31
IS7083A (is) 2003-12-18
US7125554B2 (en) 2006-10-24
SE0102327D0 (sv) 2001-06-28
JP4523773B2 (ja) 2010-08-11
HK1067980A1 (en) 2005-04-22
ES2564041T3 (es) 2016-03-17
NZ529827A (en) 2005-06-24
HRP20031054B1 (hr) 2016-12-30
US7615225B2 (en) 2009-11-10
RU2307837C2 (ru) 2007-10-10
IL159562A0 (en) 2004-06-01
CZ307180B6 (cs) 2018-02-28
BG66321B1 (bg) 2013-05-31
BRPI0210568B8 (pt) 2021-05-25
US20030039655A1 (en) 2003-02-27
CA2451847C (en) 2012-10-16
US20070082001A1 (en) 2007-04-12
JP2005503362A (ja) 2005-02-03
IL159562A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
NO333676B1 (no) Nytt konstruert superantigen for human terapi
RU2687143C2 (ru) Модифицированный экзотоксин а псевдомонад
Osička et al. Delivery of CD8+ T-cell epitopes into major histocompatibility complex class I antigen presentation pathway by Bordetella pertussis adenylate cyclase: delineation of cell invasive structures and permissive insertion sites
ES2242222T3 (es) Superantigenos modificados/quimericos y su uso.
KR100537292B1 (ko) 변이/키메라 초항원의 접합체 및 그 제약학적 조성물
ES2284209T3 (es) Citolisis de celulas diana por conjugados de superantigenos que inducen la activacion de celulas t.
EP3352779A1 (en) Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
CN110785435A (zh) 与il-12和il-18的基于il-15的融合物
KR20140033391A (ko) 면역원성이 보다 낮은 t 세포 및/또는 b 세포 에피토프를 갖는 슈도모나스 외독소 a
NO320151B1 (no) Konjugat mellom en biospesifikk affinitetsmotpart og et peptid avledet fra et superantigen som er kovalent bundet til hverandre
CN110305220B (zh) 一种癌靶向增强型抗肿瘤融合蛋白及制备方法及用途
JP6203372B2 (ja) サルシン及び他の関連する真菌リボトキシンに由来するリボトキシン分子
AU2002315979B2 (en) A novel engineered superantigen for human therapy
AU2002315979A1 (en) A novel engineered superantigen for human therapy

Legal Events

Date Code Title Description
MK1K Patent expired